In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 μM in P388/dx cells.
A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. By competitively binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle, Bosentan offset the effect of endothelin which is an extremely potent endogenous vasoconstrictor and broncho-constrictor. In addition, Bosentan decreases both pulmonary and systemic vascular resistance and is particularly applied in the treatment of pulmonary arterial hypertension. 
In vitro: A study was performed in vitro to measure the influence of Bosentan on the angiogenic performance of dermal microvascular endothelial cells (MVECs) and to detect the capacity of Bosentan in offsetting the antiangiogenic effects of systemic sclerosis sera. It was found that Bosentan significantly increased cell viability and offset the antiangiogenic effects of systemic sclerosis sera on dermal MVECs. 
In vivo: A study was conducted to investigate the effect of Bosentan on plasma leptin level after myocardial infarction in Wistar rats. After oral administration of Bosentan once daily at the dose of 100 mg/kg for 2 days, concentration of leptin in plasma significantly increased. This finding revealed that Bosentan played an crucial role on regulating leptin concentration in ischemic cardiovascular pathology. 
Clinical trials: A double-blind, placebo-controlled clinical trial was conducted to study the effect of bosentan on exercise capacity in a larger number of patients. 213 patients with pulmonary arterial hypertension were administered with 62.5 mg Bosentan twice daily for 4 weeks followed by either of two doses of Bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. It was found that 125 mg Bosentan was well tolerated and beneficial in patients with pulmonary arterial hypertension. 
 Ostrowski RP, Januszewski SA, Kowalska ZA and Kapuscinski A. Effect of endothelin receptor antagonist bosentan on plasma leptin concentration in acute myocardial infarction in rats. Pathophysiology. 2003 Sep; 9(4): 249-56.
Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M, Guiducci S. Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. Clin Exp Rheumatol. 2015 Aug; 33(4 Suppl 91): S148-52.
Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM et, al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med. 2002 Mar; 346 (12): 896-903.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Solubility||≥28.5mg/mL in DMSO|